Samsung Bioepis Partners with Sandoz for Up to Five Biosimilar Candidates

Why It Matters

The partnership accelerates biosimilar access to blockbuster biologics, strengthening both firms’ competitive positions in a rapidly growing market and diversifying revenue streams across multiple regions.

Key Takeaways

• Up to five biosimilar candidates under joint agreement
• Samsung leads development, manufacturing, regulatory filings
• Sandoz will commercialize globally, excluding China, HK, TW, MO, KR
• Partnership builds on Stelara and Soliris biosimilar launches
• Expands biosimilar pipeline targeting inflammatory and rare diseases

Pulse Analysis

The global biosimilar market is entering a phase of rapid expansion as patents for high‑revenue biologics expire. Companies are increasingly turning to strategic alliances to share risk, combine expertise, and accelerate time‑to‑market. Samsung Bioepis, a joint venture between Samsung and Biogen, has leveraged its strong R&D platform to develop next‑generation biosimilars, while Sandoz, a Novartis subsidiary, brings deep commercial networks and regulatory experience across more than 100 countries.

Under the new agreement, Samsung Bioepis will shepherd the development, manufacturing, and regulatory filing processes for up to five biosimilar candidates, starting with SB36, a biosimilar to Entyvio (vedolizumab). Sandoz will assume responsibility for global commercialization, except for a handful of Asian markets where Samsung retains rights. This division of labor mirrors their prior collaborations on the Stelara biosimilar Pyzchiva and the Soliris biosimilar Epysqli, both of which have already secured market entry in Europe, the United States, and the Middle East‑Africa region. By aligning development and commercial strengths, the partners aim to reduce launch timelines and capture market share before competing biosimilars arrive.

The deal signals heightened competition in therapeutic areas such as inflammatory bowel disease and rare immune disorders, where biologics command premium pricing. Faster biosimilar entry can drive price reductions, broaden patient access, and pressure originator manufacturers to innovate or adjust pricing strategies. For investors and industry observers, the partnership underscores a broader trend: biotech firms are prioritizing collaborative pipelines to navigate complex regulatory landscapes and meet global demand efficiently. As more biologics lose exclusivity, similar alliances are likely to proliferate, reshaping the competitive dynamics of the pharmaceutical sector.